Overview

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Status:
Terminated

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

This randomized phase III trial studies pemetrexed disodium to see how well it works compared with erlotinib hydrochloride as second-line therapy in treating patients with non-small cell lung cancer that has spread to other places in the body. Pemetrexed disodium and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pemetrexed disodium is more effective than erlotinib hydrochloride in treating advanced non-small cell lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

National Cancer Institute (NCI)

Collaborators:

Cancer and Leukemia Group B
Eastern Cooperative Oncology Group
NCIC Clinical Trials Group
Southwest Oncology Group

Treatments:

Erlotinib Hydrochloride
Pemetrexed